{"id":392686,"date":"2020-12-03T08:33:34","date_gmt":"2020-12-03T13:33:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392686"},"modified":"2020-12-03T08:33:34","modified_gmt":"2020-12-03T13:33:34","slug":"kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/","title":{"rendered":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Dec. 3, 2020<\/span> \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.<\/a>\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2nd<\/sup>\u00a0Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10,\u00a02020 at 11:45 A.M. EST<\/span>. <\/p>\n

Dr. John de Groot<\/span>, Professor, Department of Neuro-Oncology, MD Anderson Cancer Center, and Dr. James Perry<\/span>, Professor of Neurology, at the University of Toronto<\/span> Temerty Sunnybrook Research Institute will present a talk titled “Kintara’s VAL-083: A First-in-Class Bifunctional Alkylating Agent with Promising Activity in MGMT Promoter- Unmethylated & Methylated Glioblastoma.”\u00a0 <\/p>\n

Drs. de Groot and Perry are the Principal Investigators of Kintara’s arm of the Global Coalition for Adaptive Research (GCAR) Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study.<\/p>\n

\n ABOUT GLOBAL COALITION FOR ADAPTIVE RESEARCH<\/b>\n <\/p>\n

GCAR is a 501(c)(3) nonprofit organization uniting physicians, clinical researchers, advocacy and philanthropic organizations, biopharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases by serving as sponsor of innovative and complex trials including master protocols and platform trials. GCAR is the sponsor of GBM AGILE, an adaptive platform trial for patients with GBM \u2013 the most common and deadliest of malignant primary brain tumors.<\/p>\n

To learn more about GCAR, visit\u00a0www.gcaresearch.org<\/a>\u00a0and follow us: @GCAResearch and\u00a0www.facebook.com\/GCAResearch<\/a>.<\/p>\n

\n ABOUT KINTARA<\/b>\n <\/p>\n

Located in San Diego, California<\/span>, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.<\/p>\n

Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.\u00a0 The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).<\/p>\n

VAL-083 is a\u00a0“first-in-class”,\u00a0small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara’s internal research programs and these prior\u00a0NCI-sponsored\u00a0clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of\u00a0VAL-083\u00a0in GBM.<\/p>\n

Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001\u00a0therapy has been previously studied in four Phase 2\/3 clinical trials in patients with CMBC, who had previously received chemotherapy and\/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the\u00a0REM-001\u00a0CMBC program to late-stage pivotal testing.\u00a0<\/p>\n

\n SAFE HARBOR STATEMENT<\/b>\n <\/p>\n

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and the GBM AGILE study.\u00a0 Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.\u00a0 The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company’s operations and clinical trials; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.\u00a0 These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended June 30, 2020<\/span>, the Company’s Quarterly Reports on Form 10-Q, and the Company’s Current Reports on Form 8-K.<\/p>\n

\n CONTACTS:<\/b>\n <\/p>\n

\n Investors:
<\/b>CORE IR
516-222-2560
ir@coreir.com<\/a><\/p>\n

\n Media:
<\/b>
\n Jules Abraham<\/span>
\n
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com<\/a><\/p>\n

\n

\n
\n \"Kintara
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit-301185678.html<\/a><\/p>\n

SOURCE Kintara Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2nd\u00a0Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10,\u00a02020 at 11:45 A.M. EST. Dr. John de Groot, Professor, Department of Neuro-Oncology, MD Anderson Cancer Center, and Dr. James Perry, Professor of Neurology, at the University of Toronto Temerty Sunnybrook Research Institute will present a talk titled “Kintara’s VAL-083: A First-in-Class Bifunctional Alkylating Agent with Promising Activity in MGMT Promoter- Unmethylated & Methylated Glioblastoma.”\u00a0 Drs. de Groot and Perry are the Principal Investigators of Kintara’s arm of the Global Coalition for Adaptive Research … <\/p>\n

Continue reading “Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392686","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2nd\u00a0Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10,\u00a02020 at 11:45 A.M. EST. Dr. John de Groot, Professor, Department of Neuro-Oncology, MD Anderson Cancer Center, and Dr. James Perry, Professor of Neurology, at the University of Toronto Temerty Sunnybrook Research Institute will present a talk titled “Kintara’s VAL-083: A First-in-Class Bifunctional Alkylating Agent with Promising Activity in MGMT Promoter- Unmethylated & Methylated Glioblastoma.”\u00a0 Drs. de Groot and Perry are the Principal Investigators of Kintara’s arm of the Global Coalition for Adaptive Research … Continue reading "Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T13:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit\",\"datePublished\":\"2020-12-03T13:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/\"},\"wordCount\":723,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/\",\"name\":\"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"datePublished\":\"2020-12-03T13:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/","og_locale":"en_US","og_type":"article","og_title":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2nd\u00a0Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10,\u00a02020 at 11:45 A.M. EST. Dr. John de Groot, Professor, Department of Neuro-Oncology, MD Anderson Cancer Center, and Dr. James Perry, Professor of Neurology, at the University of Toronto Temerty Sunnybrook Research Institute will present a talk titled “Kintara’s VAL-083: A First-in-Class Bifunctional Alkylating Agent with Promising Activity in MGMT Promoter- Unmethylated & Methylated Glioblastoma.”\u00a0 Drs. de Groot and Perry are the Principal Investigators of Kintara’s arm of the Global Coalition for Adaptive Research … Continue reading \"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T13:33:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit","datePublished":"2020-12-03T13:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/"},"wordCount":723,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/","name":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","datePublished":"2020-12-03T13:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-2nd-annual-glioblastoma-drug-development-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392686"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392686\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}